rethinkTHC Search
Menu
Study breakdown

Hemp-Derived CBD Sublingual Solution Reduced Anxiety in Small Open-Label Pilot

Clinical TrialPreliminary evidence
The takeaway

In a 6-week open-label trial of 12 patients, a hemp-derived CBD sublingual solution at 30 mg/day significantly reduced anxiety while improving mood, sleep, and cognitive performance.

anxiety researchers, consumers considering CBD products, clinicians advising on CBD use

What the researchers found

Patients reported significant reductions in anxiety symptoms over 6 weeks. Concurrent improvements in mood, sleep, and quality of life were observed, along with stable or improved performance on executive function and memory tests. Few side effects and no serious adverse events occurred.

Why it matters

While many commercial CBD products claim anxiety benefits, few have been tested in even basic clinical trials. This pilot provides initial clinical data on a product similar to what is commercially available.

The numbers in context

12 patients with moderate-to-severe anxiety. 30 mg/day CBD for 6 weeks. Significant anxiety reduction. Improved mood, sleep, quality of life. Stable or improved cognition. No serious adverse events.

How the study worked

Open-label pilot trial (NCT04286594) of 12 patients with at least moderate anxiety. Participants self-administered a hemp-derived, full-spectrum, high-CBD sublingual solution twice daily (target: 30 mg/day CBD) for 6 weeks. Assessments included anxiety, mood, sleep, quality of life, and neurocognitive measures.

What this study cannot tell us

No placebo control or blinding. Only 12 participants. 6-week duration only. Full-spectrum product contains trace THC (<=0.3%), so effects cannot be attributed to CBD alone. Industry-relevant product tested in a very small sample.

How to read the evidence

Open-label design with no placebo control and only 12 participants places this firmly at preliminary evidence.

When this study was published

Recently published pilot trial (NCT04286594).

The bigger picture

This is a pilot without a placebo control, so the improvements could reflect placebo effects, natural symptom fluctuation, or expectation bias. Placebo-controlled trials are needed before drawing conclusions about efficacy.

Questions still open

  • Would a placebo-controlled trial replicate these findings?
  • How much of the effect is due to CBD specifically versus the full-spectrum formulation?

Common questions

Does this prove CBD works for anxiety?
No. This open-label pilot with 12 patients and no placebo control cannot prove efficacy. It provides initial signals that warrant larger, controlled studies.
Is this the same CBD you can buy in stores?
The product was a hemp-derived, full-spectrum sublingual solution similar to commercially available products, making the results potentially more relevant to real-world use than pharmaceutical-grade CBD studies.

Read the original research

Clinical and Cognitive Improvement Following Treatment with a Hemp-Derived, Full-Spectrum, High-Cannabidiol Product in Patients with Anxiety: An Open-Label Pilot Study.

Biomedicines, 13(8)

Citation

Smith, Rosemary T; Dahlgren, Mary Kathryn; Sagar, Kelly A; Kosereisoglu, Deniz; Gruber, Staci A. (2025). Clinical and Cognitive Improvement Following Treatment with a Hemp-Derived, Full-Spectrum, High-Cannabidiol Product in Patients with Anxiety: An Open-Label Pilot Study.. Biomedicines, 13(8). https://doi.org/10.3390/biomedicines13081874

Explore the wider topic